There will be an interactive High Yield Notes module soon in microregistrar.moodlecloud.com. This will cover the areas more likely to appear in the FRCPath Microbiology examination.
See a sample below (click on the link)
https://microregistrar.com/wp-content/uploads/2026/07/AmpC_Induction_Risk_Trainer-1-1.html
Screenshot
Risk of Induction of AmpC TrainerOrganism Risk · Inducer/Substrate Logic · Drug Selection
microregistrar | Infection Institute
Revision aid, not clinical guidance. Content is for FRCPath exam preparation. Always confirm current treatment choices against local antibiogram data and national guidelines for real patients.
📋 One-page quick glance — last-minute revision
Both key tables, plus the drug of choice, all in one place. Full explanations follow below and in the other tabs.
Organism risk stratification
| Risk category | Organisms |
|---|---|
| Moderate–high risk 8–40% likelihood on treatment | Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii |
| Low risk <5% likelihood | Serratia marcescens, Morganella morganii, Providencia species |
| Less common / poorly studied | Hafnia alvei, Citrobacter youngae, Yersinia enterocolitica |
Inducers & substrates quadrant
| Strong inducer | Weak inducer | Non-inducer | |
|---|---|---|---|
| Substrate | Aminopenicillins, 1st-gen cephalosporins, cephamycins | Piperacillin, ceftriaxone, ceftazidime, aztreonam | — |
| Not a substrate | Imipenem, ertapenem, meropenem | Cefepime | Fluoroquinolones, cotrimoxazole, aminoglycosides, tetracyclines, other non-beta-lactams |
Drug of choice
Cefepime first-line for moderate–high-risk organisms (weak inducer + not a substrate — the safest combination). If unavailable: a carbapenem for serious infection, or a non-beta-lactam (ciprofloxacin, cotrimoxazole, aminoglycoside) if susceptible and safe per local resistance pattern/patient profile.
Two exam traps to remember
Citrobacter koseri does not carry AmpC (unlike C. freundii). Piperacillin/ceftriaxone/ceftazidime/aztreonam are weak inducers but good substrates — they can look safe initially, then fail mid-treatment as a derepressed mutant is selected.
🎯 Why this topic keeps coming up
This has been examined in several different formats: straightforward risk-stratification questions, “which antibiotic to avoid,” “which antibiotics are safer/less risky,” “drug of choice,” and “which organism carries the highest risk” — presented as both standalone MCQs and clinical vignettes/cases.
🧬 What AmpC induction actually is
The regulatory switch behind “safe on day 1, resistant by day 5”
- Certain Enterobacterales carry a chromosomally encoded class C beta-lactamase (AmpC), normally expressed at very low (“basal”) levels.
- Two regulatory proteins control this: AmpR (a transcriptional regulator that can act as either repressor or activator) and AmpD (an enzyme that recycles cell-wall breakdown products, called muropeptides, generated during normal peptidoglycan turnover).
- Exposure to certain beta-lactams increases the pool of unrecycled muropeptides. These bind AmpR and flip it from repressor to activator, switching on high-level, but usually transient, AmpC expression — this is “induction.”
- The clinically dangerous scenario is stable derepression: a spontaneous mutation (commonly in ampD) that locks AmpC into constitutive high-level production, which persists even after the inducing drug is stopped — this is how resistance can emerge mid-treatment on an isolate that was fully susceptible at the start.
📊 Organism risk stratification
Figures below are as stated in current IDSA guidance (2024 update) — confidence high, directly sourced
| Risk category | Organisms |
|---|---|
| Moderate–high risk 8–40% likelihood of clinically significant AmpC derepression during treatment | Enterobacter cloacae, Klebsiella aerogenes (formerly Enterobacter aerogenes), Citrobacter freundii |
| Low risk <5% likelihood | Serratia marcescens, Morganella morganii, Providencia species |
| Less common / poorly studied Carry inducible chromosomal ampC genes, but insufficient clinical data to confidently place a risk figure on them | Hafnia alvei, Citrobacter youngae, Yersinia enterocolitica |
Source check
These exact figures and groupings match the IDSA 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections, which explicitly states an 8–40% range of inducible resistance for the moderate–high-risk trio, <5% for the low-risk group, and separately flags Hafnia alvei, Citrobacter youngae, and Yersinia enterocolitica as under-studied. Confidence: high.
🔤 Mnemonics — use with a little caution
- “ECK” — Enterobacter cloacae, Citrobacter freundii, Klebsiella aerogenes — the classic “big 3” moderate–high-risk organisms, and the most solidly evidence-based grouping.
- “HECK-Yes” — an extended mnemonic adding Hafnia alvei and Yersinia enterocolitica to the ECK core. This is a more recently proposed teaching device (seen in continuing-education/opinion pieces) rather than a term used in the IDSA guidance itself — useful for recall, but be aware it bundles organisms with genuinely different levels of evidence behind them. Confidence in the mnemonic as a memory aid: high; confidence that it reflects a formally validated risk category: moderate (~75%) — flagging this distinction because it blurs a “well-evidenced trio” with a “poorly-studied trio” under one acronym.
Common trap
Citrobacter koseri does not carry an inducible chromosomal AmpC — do not confuse it with Citrobacter freundii, which does.
🧪 Extra mechanistic detail — mutation rates
In-vitro studies calculating species-specific mutation rates to AmpC derepression found a high mean mutation rate (~3 × 10⁻⁸) for Enterobacter cloacae complex, Klebsiella aerogenes, Citrobacter freundii complex, and Hafnia alvei — versus considerably lower rates in Providencia species, Serratia species, and especially Morganella morganii. This mechanistic data helps explain why the risk stratification above looks the way it does, rather than simply describing that it does.
🔑 Two independent properties, not one
Every beta-lactam can be described by two separate properties with respect to AmpC:
- How strongly it induces ampC expression (strong / weak / non-inducer).
- Whether it is a good substrate for the AmpC enzyme once expressed — i.e. whether AmpC can actually hydrolyse and destroy it.
Why this matters
These two properties are independent — a drug can strongly induce AmpC yet remain completely stable to it (safe), or barely induce it at all yet be destroyed the moment AmpC is switched on by something else (dangerous). This mismatch is the basis of nearly every exam question on this topic.
🧮 The quadrant table
| Strong inducer | Weak inducer | Non-inducer | |
|---|---|---|---|
| Substrate (hydrolysed by AmpC) | Aminopenicillins, 1st-generation cephalosporins, cephamycins | Piperacillin, ceftriaxone, ceftazidime, aztreonam | — |
| Not a substrate (stable to AmpC hydrolysis) | Imipenem, ertapenem, meropenem | Cefepime | Fluoroquinolones, cotrimoxazole, aminoglycosides, tetracyclines, other non-beta-lactams |
🔎 Reading the four corners
- Strong inducer + substrate (aminopenicillins, 1st-gen cephalosporins, cephamycins) — the “obviously bad” corner: these drive AmpC expression up and get destroyed by it. Intrinsically unreliable against organisms with inducible AmpC.
- Weak inducer + substrate (piperacillin, ceftriaxone, ceftazidime, aztreonam) — the exam-favourite “danger zone.” These look deceptively safe because they don’t strongly switch on AmpC themselves, but if a resistant subpopulation is selected (by any trigger, including a different concurrent drug or spontaneous derepression), these agents will fail — because they are still readily hydrolysed once AmpC is up.
- Strong inducer + not a substrate (carbapenems: imipenem, ertapenem, meropenem) — potently switch AmpC on, but remain effective anyway because AmpC cannot hydrolyse them. This is why carbapenems are safe against high-risk organisms despite being the strongest inducers.
- Weak inducer + not a substrate (cefepime) — the best combination available among the cephalosporins: minimal induction and resistance to hydrolysis. This dual property is exactly why cefepime is the preferred first-line agent for moderate–high-risk organisms.
- Non-inducer, not relevant as a substrate (fluoroquinolones, cotrimoxazole, aminoglycosides, tetracyclines, other non-beta-lactams) — AmpC only hydrolyses beta-lactams, so non-beta-lactam classes are simply outside this whole system.
Exam pearl
If a question describes an organism from the moderate–high-risk group responding well initially to ceftriaxone/ceftazidime/piperacillin, then relapsing with a resistant isolate during the same admission — that is a description of the “weak inducer + substrate” trap, not treatment failure due to non-compliance or a new infection.
💊 Drug of choice
- Cefepime is preferred first-line for infections due to moderate–high-risk organisms (Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii) — it combines weak AmpC induction with resistance to AmpC hydrolysis.
- If cefepime is not available (not stocked in every UK trust): a carbapenem for serious infection, or a non-beta-lactam (ciprofloxacin, cotrimoxazole, an aminoglycoside, etc.) if the isolate is susceptible and this is safe based on local resistance patterns and the individual patient’s profile.
Added nuance from current guidance (not in the original source notes, included for completeness)
IDSA 2024 guidance refines the cefepime recommendation by MIC: cefepime is preferred when the cefepime MIC is ≤2 µg/mL. For isolates with a cefepime MIC of 4–8 µg/mL, a carbapenem is preferred instead — this MIC range has been associated with a substantially higher likelihood of co-existing ESBL production, and one cited cohort found notably worse outcomes when cefepime was used in that specific subgroup. Confidence: high (directly stated in the current IDSA guidance), but included as supplementary detail since it wasn’t part of the original notes.
🗂️ How this gets tested — recap
Keep an eye out for these question framings, all covering the same underlying logic:
- “Which organism carries the highest risk of AmpC-mediated resistance emerging on treatment?”
- “Which antibiotic should be avoided / is safest in this scenario?”
- “What is the most appropriate drug of choice for this infection?”
- A case vignette showing initial improvement then relapse with a resistant organism during a single admission.
⚖️ Stewardship & evolving evidence
- Always cross-check against your local antibiogram and trust/national guidelines — regional resistance patterns and formulary availability (e.g. cefepime is not stocked everywhere in the UK) affect real-world choices.
- The role of piperacillin-tazobactam versus cefepime for AmpC-risk organisms remains an area of ongoing debate in the literature, with some studies suggesting comparable outcomes for lower-risk infections and others favouring cefepime/carbapenems — this module reflects current mainstream teaching rather than a settled, unanimous consensus.
🃏 Flashcard deck
Tap to flip
1 / 12
🎯 Quick test
XP: 0Q1